Epizyme Long Term Debt 2012-2022 | EPZM

Epizyme long term debt from 2012 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Epizyme Annual Long Term Debt
(Millions of US $)
2021 $216
2020 $216
2019 $23
2018 $
2017 $
2016 $0
2015 $1
2014 $
2013 $
2012 $
2011 $
Epizyme Quarterly Long Term Debt
(Millions of US $)
2022-03-31 $217
2021-12-31 $216
2021-09-30 $216
2021-06-30 $216
2021-03-31 $216
2020-12-31 $216
2020-09-30 $69
2020-06-30 $68
2020-03-31 $48
2019-12-31 $23
2019-09-30
2019-06-30 $8
2019-03-31 $9
2018-12-31
2018-09-30 $0
2018-06-30 $0
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $1
2015-12-31 $1
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.157B $0.037B
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.111B 10.23
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.588B 16.71
Biohaven Pharmaceutical Holding (BHVN) United States $10.141B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.081B 0.00
Arcus Biosciences (RCUS) United States $1.832B 46.46
Emergent Biosolutions (EBS) United States $1.646B 7.05
Myovant Sciences (MYOV) United Kingdom $1.264B 0.00
Zymeworks (ZYME) Canada $0.364B 0.00
Gelesis Holdings (GLS) United States $0.116B 0.00
Ambrx Biopharma (AMAM) United States $0.111B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00